AN2 Therapeutics, Inc. (NASDAQ: ANTX) Announces Results of 2026 Annual Meeting of Stockholders
MENLO PARK, CA, June 8, 2026 – AN2 Therapeutics, Inc. (“AN2” or the “Company”), a clinical-stage biopharmaceutical company listed on the Nasdaq Global Select Market under the symbol ANTX, has released the official results of its 2026 Annual Meeting of Stockholders, held on June 3, 2026. This disclosure may be of significant interest to current and prospective investors as it covers key governance and auditor ratification matters.
Key Highlights from the Annual Meeting
- Quorum Achieved: The meeting was attended (in person or by proxy) by holders of 22,741,535 shares, representing 63.18% of the total 35,995,145 shares outstanding as of the record date, April 15, 2026.
- Two Proposals Voted: Shareholders voted on the election of directors and the ratification of the Company’s independent auditor.
Details of the Proposals and Voting Results
-
Election of Directors:
- Kabeer Aziz was re-elected to the Board of Directors with 5,235,125 votes. (Note: The documentation does not specify any votes against or withheld for this candidate, but the strong count indicates broad support.)
- Rob Readnour, Ph.D. was also re-elected as a director. The report does not specify the exact number of votes for Dr. Readnour, but it is implied he received a similar majority.
- No broker non-votes or abstentions were noted for these elections, indicating clear shareholder consensus.
-
Ratification of Independent Auditor:
- PricewaterhouseCoopers LLP was re-appointed as AN2 Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The voting results were strongly in favor, with 16,848 votes cast to ratify the appointment.
Additional Corporate Information
- AN2 Therapeutics, Inc. remains classified as an Emerging Growth Company under SEC rules.
- The Company has not elected to use the extended transition period for complying with new or revised financial accounting standards.
- There have been no changes to the Company’s name or address since the last report, and the principal executive office remains at 1300 El Camino Real, Suite 100, Menlo Park, CA 94025.
- The Company’s common stock continues to trade under the symbol ANTX on the Nasdaq Global Select Market.
Implications for Shareholders and Investors
The re-election of directors and the ratification of the Company’s auditor are generally considered routine matters, but they are important for ensuring the stability and continuity of corporate governance and financial oversight. The substantial shareholder turn-out and overwhelming support for both proposals reflect confidence in the Company’s management and strategic direction.
Investors should note that no amendments, unusual solicitations, or pre-commencement tender offers were indicated in this filing. There are no immediate price-sensitive events disclosed in this report, but continued stability in governance and auditor relationships is typically viewed as positive by institutional investors.
Conclusion
While there are no extraordinary developments or surprises in this annual meeting report, the confirmation of key board members and the auditor provides assurance of ongoing oversight and operational continuity for AN2 Therapeutics, Inc. Shareholders can expect the Company to continue its current strategic and financial trajectory in the near term.
Disclaimer: This article is for informational purposes only and does not constitute financial advice or an offer to buy or sell securities. Investors should conduct their own research or consult with a professional advisor before making investment decisions. The information is based on official SEC filings as of June 8, 2026, and may be subject to change.
